



Subst. for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Sheet 1 of 7 Docket Number 068911-0160

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US 3,552,975	01/5/1971	Worden, et al.	
	A2	US 3,720,517	03/13/1973	Bavisotto, et al.	
	A3	US 3,932,603	06/13/1976	Haas	
	A4	US 3,933,919	01/20/1976	Wilkinson	
	A5	US 3,965,188	06/22/1976	Westermann, et al.	
	A6	US 4,123,561	10/31/1978	Grant	
	A7	US 4,133,903	01/09/1979	Thiele, et al.	
	A8	US 4,148,873	04/10/1979	Owades	
	A9	US 4,154,865	05/15/1979	Grant	
	A10	US 4,389,421	06/21/1983	Palamand	
	A11	US 4,170,638	10/09/1979	Owades	
	A12	US 4,401,684	08/30/1983	Versluys	
	A13	US 4,473,551	09/25/1984	Schinitsky	
	A14	US 4,554,170	11/19/1985	Panzer, et al.	
	A15	US 4,644,084	02/17/1987	Cowles, et al.	
	A16	US 4,692,280	09/08/1987	Spinelli	
	A17	US 4,767,640	08/30/1998	Goldstein, et al.	
	A18	US 4,857,554	08/15/1989	Kallimanis	
	A19	US 5,006,337	04/09/1991	Motitschke, et al.	
	A20	US 5,013,571	05/07/1991	Hay	
	A21	US 5,041,300	08/20/1991	Todd et al.	
	A22	US 5,073,396	12/17/1991	Todd, Jr.	
	A23	US 5,082,975	01/21/1992	Todd, Jr., et al.	
	A24	US 5,155,276	10/13/1992	Paul	
	A25	US 5,166,449	11/24/1992	Todd, Jr., et al.	
	A26	US 5,286,506	02/15/1994	Millis, et al.	
	A27	US 5,296,637	02/01/2000	Ting, et al.	
	A28	US 5,387,425	02/07/1995	Hsu, et al.	
	A29	US 5,604,263	02/18/1987	Tobe, et al.	
	A30	US 5,624,236	11/23/1993	Ogasahara, et al.	
	A31	US 5,641,517	06/24/1997	Eskeland, et al.	
	A32	US 5,827,895	10/27/1998	Nutter, et al.	
	A33	US 5,968,539	10/19/1999	Beerse et al.	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Subst. for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/590,424
				Filing Date	08/23/06
				First Named Inventor	John Babish
				Art Unit	
				Examiner Name	
Sheet	2	of	7	Docket Number	068911-0160
U.S. PATENT DOCUMENTS CONT.					
EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A34	US 5,919,813	07-06-1999	De Juan	
	A35	US 6,020,019	05/21/2002	Ting et al.	
	A36	US 6,129,907	02/01/2000	Sreenivasan, et al.	
	A37	US 6,200,594	03/13/2001	Ernest et al.	
	A38	US 6,383,527	05/07/2002	Artman, et al.	
	A39	US 6,391,346	05/21/2002	Newmark, et al.	
	A40	US 6,440,465	08/27/2002	Meisner	
	A41	US 6,447,762	09/10/2002	Galcerá	
	A42	US 6,583,322	06/24/2003	Shalai, et al.	
	A43	US 6,689,388	02/10/2004	Kuhrts	
	A44	US 6,790,459	09/00/2004	Cheng, et al.	
	A44	US 6,801,860	10/05/2004	Dessen et al.	
	A45	US 7,279,185	10/29/2007	Babish, et al.	
	A46	US 20020076452	06/20/2002	Babish, et al.	
	A47	US 20020077299	06/20/2002	Babish, et al.	
	A48	US 20020086062	07/04/2002	Kuhrts	
	A49	US 20020086070	07/04/2002	Kuhrts	
	A50	US 20020028852	03/07/2002	Ghai, et al.	
	A51	US 20030077313	04/24/2003	Schwartz, Robert ; et al.	
	A52	US 20030096027	05/22/2003	Babish, et al.	
	A53	US 20030113393	06/19/2004	Babish, et al.	
	A54	US 20030133958	07/17/2003	Kuno, et al.	
	A55	US 20030180402	09-25-2003	Jia et al.	
	A56	US 20040072900	04/15/2004	Artman et al.	
	A57	US 20040086580	05/06/2004	Tripp, et al.	
	A58	US 20040137096	07/15/2004	Kuhrts	
	A59	US 20040219240	11/04/2004	Babish, et al.	
	A60	US 20040151792	08/00/2004	Tripp, et al.	
	A61	US 20040138199	07/00/2004	Gogliotti, et al.	
EXAMINER				DATE CONSIDERED	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/590,424
Filing Date	08/23/06
First Named Inventor	John Babish
Art Unit	
Examiner Name	

FOREIGN PATENT DOCUMENTS

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Subst. for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/590,424
				Filing Date	08/23/06
				First Named Inventor	John Babish
				Art Unit	
				Examiner Name	
Sheet	4	of	7	Docket Number	068911-0160
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
	C1	"Information on arthrotrim product", downloaded from Internet 8/30/02.			
	C2	"Information on Zyflamend and Zyflamend PM", downloaded from Internet 8/30/02.			
	C3	"Information on Hops and Beer Flavours", downloaded from internet 02/15/2005			
	C4	Anto, <i>et al.</i> Pharm. Pharmacol. Comm. 4:103-106 (1998)			
	C5	Bermejo, <i>et al.</i> Rev. Esp. Enferm. Dig. 95: 621-624 and 625-628 (2003)			
	C6	Brown, <i>et al.</i> J. Chem. Soc. 545 (1959)			
	C7	Byrne, <i>et al.</i> J. Chem. Soc. (c):2810 (1971)			
	C8	Carroccio, <i>et al.</i> Clin. Chem. 49:861-867 (2003)			
	C9	Carson, J. Am. Chem. Soc. 73:1850-1851 (1951)			
	C10	Chandra, <i>et al.</i> Indian J. Medical Research 60(1):138-142 (1972)			
	C11	Charlier, <i>et al.</i> Eur. J. Med. Chem. 38:645-659 (2003)			
	C12	Chou, <i>et al.</i> Eur. J. Biochem. 115:207-216 (1981)			
	C13	Chou, <i>et al.</i> Adv enzyme regul 22:27-55 (1984)			
	C14	Chou, <i>et al.</i> J. Biol. Chem. 252:6438-6442 (1977)			
	C15	Chou, <i>et al.</i> J. Theor. Biol. 35:285-297 (1972)			
	C16	Chou, <i>et al.</i> Trends Pharm. Sci. 4:450-454 (1983)			
	C17	Chou, J. Theor. Biol. 59:253-276 (1976)			
	C18	Cohen, P., Perspectives, 2002 Nature Publishing Group, Vol. 1, pp. 309-315.			
	C19	Costa, <i>et al.</i> Digest. Liver Dis. 35:642-647 (2003)			
	C20	Davies, WL. Abstract - Fertiliser, Feeding stuffs and Farm Supplies J. 11:694 (1926)			
	C21	Ding, <i>et al.</i> Biochem. Biophys. Res. Comm. 261:218-223 (1999)			
	C22	Exercise as Treatment for Arthritis, Rheumatic and Immunologic Diseases, Cleveland Clinic, www.clevelandclinic.org, March 14, 2000			
	C23	Friedman, <i>et al.</i> J Cutan Med. Surg. 6(5):449-459 (2002)			
	C24	Germany, "The Absolutely German Drink," contents of beer, 2004, 5 pages.			
	C25	Gerhäuser, C., European Journal of Cancer 41 (2005), pp. 1941-1954			
	C26	Goldstein, <i>et al.</i> Am. J. Gastroenterol. 96:1019-1027 (2001)			
	C27	Halter, <i>et al.</i> Gut 49:443-453 (2001)			
	C28	Hamberg, <i>et al.</i> J. Bio. Chem. 246:6713-6721 (1971)			
	C29	Huang, <i>et al.</i> Cancer Res. 51:813-819 (1991)			
	C30	International Search Report for PCT/US02/19617			
	C31	International Search Report for PCT/US04/16043			
	C32	Jach, Przegl Dermatol. 65(4):379-382 (1978)			
	C33	Kanematsu, <i>et al.</i> J Bone Miner Res 12(11):1789-1796 (1997)			
	C34	Lopes, Curr. Med Res Opin. 8:145-149 (1982)			
	C35	Meling, <i>et al.</i> Scand. J. Gastroenterol. 31:339-344 (1996)			
	C36	Noreen, <i>et al.</i> J. Nat. Prod 61:2-7 (1998)			
	C37	Pairet, <i>et al.</i> Inflamm. Res 47, Supplement 2s93-s101 (1998)			
	C38	Panglisch, monafsschrift fuer brauwissen schaft, 1990, 43(1), 4-16			
	C39	Pippa, <i>et al.</i> Scand. J. Gastroenterol. Suppl. 167:32-35 (1989)			
	C40	Plewig, <i>et al.</i> J Invest. Dermatol. 65(6):532-536 (1975)			
	C41	Poullis, <i>et al.</i> J. Gastroenterol. Hepatol. 18:756-762 (2003)			
	C42	Ringbom, <i>et al.</i> J. Nat Prod 61:1212-1215 (1998)			
	C43	Provital Group, Rosemary-eco Botany, 2007, 9 pages			
EXAMINER				DATE CONSIDERED	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Subst. for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/590,424
				Filing Date	08/23/06
				First Named Inventor	John Babish
				Art Unit	
				Examiner Name	
Sheet	5	of	7	Docket Number	068911-0160
	C44	Røseth, digest. Liver Dis. 35:607-609 (2003)			
	C45	Schjerven, et al. Br. J. Dermatol. 149:484-491 (2003)			
	C46	Shah, et al. Gut 48:339-346 (2001)			
	C47	Shimamura, et al. Biochem. Biophys. Res. Comm. 289:220-224 (2001)			
	C48	Shureiqi, et al. Cancer res. 61:6307-6312 (2001)			
	C49	Sivri, fundam. Clinic. Pharmacol. 18:23-31 (2004)			
	C50	Smith, et al., Natural Foam Stabilizing and Bittering Compounds Derived From Hops, Journal of the American Society of Brewing Chemists, Vol. 56, No. 2, 1998, pp. 52-57			
	C51	Subbaramaiah, et al. Cancer Res. 60:2399-2404 (2000)			
	C52	Suh, et al. Cancer Res. 58:717-723 (1988)			
	C53	Tagashira, et al., Biosci. Biotech. Biochem. 59(4):740-742 (1996)			
	C54	Thomas m. Newmark and paul schulick, 'Beyond Aspirin nature's answer to arthritis, cancer & alzheimer's disease,' hohm press (2000) release 7; pp. 147-151, 248.			
	C55	Tibble, et al. Drugs Today 37:85-96 (2001)			
	C56	Tibble, et al. Gut 45:362-366 (1999)			
	C57	Tobe, et al. Biosci. Biotech. Biochem 61(1):158-159 (1997)			
	C58	Vanhoenacker, et al., Analysis of iso-alpha-acids and reduced iso-alpha-acids in beer by direct injection and liquid chromatography with ultraviolet absorbance detection or with mass spectrometry, Journal of Chromatography, Vol. 1035, No.1, (4-30-2004), pp.53-61			
	C59	Wang, et al. Free Radical Biology & Medicine 27:612-616 (1999)			
	C60	Warner, et al. Proc Natl Acad Sci USA 96:7563-7568 (1999)			
	C61	Yamamoto, et al. Abstract - Prostaglandins & Other Lipid Mediators 59:1-235 (1999)			
	C62	Yamamoto, FEBS Letters 465:103-106 (2000)			
	C63	Yui, et al. Biol. Pharm. Bull. 26:753-760 (2003)			
	C64	Supplementary Partial European Search Report for EP Application No. 05723895.8 (5 pages)			
	C65	International Search Report for related PCT Application No. PCT/US06/30920			
	C66	Gilani, A.H., Phytotherapy Research, 13 (1999), pp. 665-669			
	C67	International Search Report for related PCT Application No.: PCT/US06/47196			
	C68	Kaltner, Investigation of Formation of Hops Aroma and Technological Measures for Production of Hops-Aromatic Beers, Technical University of Munich, Approved Dissertation			
	C69	Stevens, et al., Xanthohumol and Related Prenylflavonoids from Hops and Beer: To your Good Health!, Sciencedirect, November 2007, 2 pp (abstract)			
	C70	Ward, et al., Therapeutic Potential of Phosphoinositide 3-Kinase Inhibitors, Chemistry & Biology, Vol. 10, 207-213, March 2003			
	C71	Arner, P., Insulin Resistance in Type 2 Diabetes – Role of the Adipokines. Curr. Mol. Med.; 5(3):333-339, (May 2005).			
	C72	Berenbaum, M.C., What is Synergy?: Pharmacol Rev; 41(2):93-141 (1989)			
	C73	Boden, G., Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM. Diabetes 46(1): 3-10, (1997).			
	C74	Cho et al., Akt1/PKBa Is Required for Normal Growth but Dispensable for Maintenance Glucose Homeostasis in Mice, J Biol Chem 276:38349-38352 (2001).			
EXAMINER				DATE CONSIDERED	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Subst. for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/590,424
				Filing Date	08/23/06
				First Named Inventor	John Babish
				Art Unit	
				Examiner Name	
Sheet	6	of	7	Docket Number	068911-0160
	C75	Cho <i>et al.</i> , Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKB β), <i>Science</i> 292:1728-1731 (2001)			
	C76	Chou, T.C., <i>et al.</i> , Quantitative Analysis of Dose-effect Relationships; The Combined Effects of Multiple Drugs or Enzyme Inhibitors; <i>Adv Enzyme Regul</i> 22:27-55, (1984).			
	C77	Choy, <i>et al.</i> , Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis; <i>New England Jour. Med.</i> 344:pp. 907-916, (2001).			
	C78	Crowley, <i>et al.</i> , A Critical Role for Syk in Signal Transduction and Phagocytosis Mediated by Fc γ Receptors on Macrophages; <i>J. Exp. Med.</i> 186:1027-1039, (1997).			
	C79	Dignam, <i>et al.</i> , Accurate Transcription Initiation by RNA Polymerase II in a Soluble Extract From Isolated Mammalian Nuclei; <i>Nucl Acids Res</i> 11:1475-1489, (1983).			
	C80	Fasshauer, M., <i>et al.</i> , Hormonal Regulation of Adiponectin Gene Expression in 3T3-L1 Adipocytes; <i>Biochem Biophys Res Commun</i> , 290:1084-1089, (2002).			
	C81	Hibi, M., <i>et al.</i> , IL-6 Cytokine Family and Signal Transduction: A Model of the Cytokine System. <i>J Mol Med.</i> 74(1):1-12, (Jan 1996).			
	C82	Hofstee, B.H., Non-inverted Versus Inverted Plots in Enzyme Kinetics; <i>Nature</i> 184:1296-1298, (1959).			
	C83	Hutchcroft, J. E., <i>et al.</i> , Association of the 72-kDa Protein-tyrosine Kinase Ptk72 with the B-cell Antigen Receptor; <i>J. Biol. Chem.</i> 267:8613-8619, (1992).			
	C84	Jiang, K., <i>et al.</i> , Regulation of Akt-dependent Cell Survival by Syk and Rac; <i>Blood</i> 101, pp. 236-244, (2003).			
	C85	Kasturi, R., <i>et al.</i> , Hormonal Regulation of Stearoyl Coenzyme A Desaturase Activity and Lipogenesis During Adipose Conversion of 3T3-L1 Cells; <i>J Biol Chem</i> , 257:12224-12230, 1982.			
	C86	Li, Y., <i>et al.</i> , Differential Gene Regulation by PPAR γ Agonist and Constitutively Active PPAR γ 2; <i>Mol. Endocrinol.</i> , 16:1040-1048, (2002).			
	C87	Martin, G., <i>et al.</i> PPAR γ Activators Improve Glucose Homeostasis by Stimulating Fatty Acid Uptake in the Adipocytes; <i>Atherosclerosis</i> 137 Suppl:S75-S80, (1998).			
	C88	Moon KD, <i>et al.</i> , Molecular Basis for a Direct Interaction between the Syk Protein-tyrosine Kinase and Phosphoinositide 3-Kinase; <i>J. Biol. Chem.</i> 280, No. 2, Issue of January 14, pp. 1543-1551, (2005).			
	C89	Oakes, N. D., <i>et al.</i> , Thiazolidinediones Increase Plasma-Adipose Tissue FFA Exchange Capacity and Enhance Insulin-Mediated Control of Systemic FFA Availability; <i>Diabetes</i> 50(5):1158-1165, (2001).			
	C90	Parker, P. J., <i>et al.</i> , Glycogen Synthase from Rabbit Skeletal Muscle; Effect of Insulin on the State of Phosphorylation of the Seven Phosphoserine Residues in vivo; (1983) <i>Eur. J. Biochem.</i> 130:227-234.			
	C91	Raeder, E. M., <i>et al.</i> , Syk Activation Initiates Downstream Signaling Events During Human Polymorphonuclear Leukocyte Phagocytosis, <i>J. Immunol.</i> 163: 6785-6793, (1999)			
	C92	Raz, I, <i>et al.</i> ; Diabetes: insulin resistance and derangements in lipid metabolism. Cure Through intervention in fat transport and storage; <i>Diabetes Metab. Res. Rev.</i> ; 21: 3-14 (2005).			
	C93	Stumvoll, M., <i>et al.</i> , Glitazones: clinical effects and molecular mechanisms. <i>Ann Med</i> 34(3): 217-224, (2002).			
EXAMINER				DATE CONSIDERED	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Subst. for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/590,424
				Filing Date	08/23/06
				First Named Inventor	John Babish
				Art Unit	
				Examiner Name	
Sheet	7	of	7	Docket Number	068911-0160
	C94	van der Kraan P.M., et al., Anabolic and destructive mediators in osteoarthritis. Curr Opin Clin Nutr Metab Care,3:205-211, 2000.			
	C95	Verdu et al., Cell-autonomous regulation of cell and organ growth in Drosopholia by Akt/PKB; Nat cell Biol 1:500-505 (1999).			
	C96	Ward, S.G., et al., Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol. Aug;3(4):426-434, (2003).			
	C97	Warner, T.D. et al. Nonsteroidal drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA 96:7563-7568, (1999).			
	C98	Wong B.R., et al., Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 13:743-762, 2004.			
	C99	Yajima, H., et al., Isohumulones, Bitter Acids Derived From Hops, Activate Both Peroxisome Proliferator-Activated Receptor Alpha and Gamma and Reduce Insulin Resistance. J Biol Chem, 279: 33456-33462, (2004).			
	C100	Yamada, T., et al., Association with B-cell antigen cell antigen receptor with protein-tyrosine kinase-P72(Syk) and activation by engagement of membrane IgM; Eur. J. Biochem. 213: 455-459, (1993).			
	C101	Yamauchi, T., et al., The mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor gamma (PPARGgamma) Deficiency and PPARGgamma Agonist Improve Insulin Resistance; J Biol Chem 276(44): 41245-41254, (2001).			
	C102	Yang, W. S., et al., Weight Reduction Increases Plasma Levels of an Adipose-Derived Anti-Inflammatory Protein, Adiponectin; J Clin Endocrinol Metab 86(8): 3815-3819, (2001).			
	C103	El-Toumy et al., Polyphenols from Acacia Nilotica Leaves and Evaluation of Antihyperglycemic Effect of Aqueous Extract, Bulletin of the Faculty of Pharmacy (2004), 42 (2), 317-325			
EXAMINER			DATE CONSIDERED		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.